Dec 17, 2020
GHB was awarded new technology at the 2020 Blockchain Awards Ceremony
Sep 16, 2019
Harmony Biosciences To Present Clinical Data On WAKIX® (pitolisant) At Upcoming World Sleep 2019
Jul 16, 2019
Narcolepsy Drugs Market to Garner $5.36 Bn, Globally, by 2026 at 10.3% CAGR: Says Allied Market Research
Jun 04, 2019
Harmony Biosciences To Present New Data On Pitolisant In Patients With Narcolepsy At SLEEP 2019 Meeting
May 09, 2019
Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
Dec 21, 2018
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Nov 29, 2018
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
Oct 29, 2018
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jun 27, 2018
Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jun 03, 2018
Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy
Feb 13, 2018
Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018
Jan 02, 2018
Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8
Dec 07, 2017
Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
Nov 09, 2017
Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences
Oct 24, 2017
Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting
Oct 05, 2017
Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting
Aug 30, 2017
Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference
Aug 03, 2017
Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update
Jun 06, 2017
Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy